The overall results showed that Kras mutations has 34–87.5% of sensitivity for detecting CRC patients and the specificity was very high, reaching in some studies 100% (Dong et al., 2001; Doolittle et al., 2001; Rengucci et al., 2001; Calistri et al., 2003; Chien et al., 2007; Mixich et al., 2007; Zhang et al., 2011a). Here, KRAS is linked to colorectal carcinoma.